Literature DB >> 25627979

Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Pubudu M Peiris1, Aaron Abramowski2, James Mcginnity3, Elizabeth Doolittle1, Randall Toy1, Ramamurthy Gopalakrishnan4, Shruti Shah3, Lisa Bauer5, Ketan B Ghaghada6, Christopher Hoimes7, Susann M Brady-Kalnay8, James P Basilion9, Mark A Griswold10, Efstathios Karathanasis11.   

Abstract

Glioblastoma multiforme is generally recalcitrant to current surgical and local radiotherapeutic approaches. Moreover, systemic chemotherapeutic approaches are impeded by the blood-tumor barrier. To circumvent limitations in the latter area, we developed a multicomponent, chain-like nanoparticle that can penetrate brain tumors, composed of three iron oxide nanospheres and one drug-loaded liposome linked chemically into a linear chain-like assembly. Unlike traditional small-molecule drugs or spherical nanotherapeutics, this oblong-shaped, flexible nanochain particle possessed a unique ability to gain access to and accumulate at glioma sites. Vascular targeting of nanochains to the αvβ3 integrin receptor resulted in a 18.6-fold greater drug dose administered to brain tumors than standard chemotherapy. By 2 hours after injection, when nanochains had exited the blood stream and docked at vascular beds in the brain, the application of an external low-power radiofrequency field was sufficient to remotely trigger rapid drug release. This effect was produced by mechanically induced defects in the liposomal membrane caused by the oscillation of the iron oxide portion of the nanochain. In vivo efficacy studies conducted in two different mouse orthotopic models of glioblastoma illustrated how enhanced targeting by the nanochain facilitates widespread site-specific drug delivery. Our findings offer preclinical proof-of-concept for a broadly improved method for glioblastoma treatment. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25627979      PMCID: PMC4383708          DOI: 10.1158/0008-5472.CAN-14-1540

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors.

Authors:  Kimberley M Laginha; Sylvia Verwoert; Gregory J R Charrois; Theresa M Allen
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

2.  Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.

Authors:  S Mankhetkorn; F Dubru; J Hesschenbrouck; M Fiallo; A Garnier-Suillerot
Journal:  Mol Pharmacol       Date:  1996-03       Impact factor: 4.436

3.  New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

Authors:  C Rousselle; P Clair; J M Lefauconnier; M Kaczorek; J M Scherrmann; J Temsamani
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

Review 4.  Delivery systems and molecular targets of mechanism-based therapies for GBM.

Authors:  Surasak Phuphanich; Daniel J Brat; Jeffrey J Olson
Journal:  Expert Rev Neurother       Date:  2004-07       Impact factor: 4.618

5.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.

Authors:  S K Hobbs; W L Monsky; F Yuan; W G Roberts; L Griffith; V P Torchilin; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

6.  Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse.

Authors:  B J Marafino; S N Giri; D M Siegel
Journal:  J Pharmacol Exp Ther       Date:  1981-01       Impact factor: 4.030

7.  The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.

Authors:  H Brem; M G Ewend; S Piantadosi; J Greenhoot; P C Burger; M Sisti
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

8.  In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier.

Authors:  T Ohnishi; I Tamai; K Sakanaka; A Sakata; T Yamashima; J Yamashita; A Tsuji
Journal:  Biochem Pharmacol       Date:  1995-05-17       Impact factor: 5.858

9.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

10.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

Authors:  P C Brooks; S Strömblad; R Klemke; D Visscher; F H Sarkar; D A Cheresh
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  29 in total

Review 1.  Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.

Authors:  Prabhani U Atukorale; Gil Covarrubias; Lisa Bauer; Efstathios Karathanasis
Journal:  Adv Drug Deliv Rev       Date:  2016-09-15       Impact factor: 15.470

2.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

3.  Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size.

Authors:  Nathan Andrew Rohner; Susan Napier Thomas
Journal:  ACS Biomater Sci Eng       Date:  2016-11-18

Review 4.  Perspectives on Dual Targeting Delivery Systems for Brain Tumors.

Authors:  Huile Gao
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-08       Impact factor: 4.147

5.  Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy.

Authors:  Xiangdong Xue; Yee Huang; Xinshuai Wang; Zhongling Wang; Randy P Carney; Xiaocen Li; Ye Yuan; Yixuan He; Tzu-Yin Lin; Yuanpei Li
Journal:  Biomaterials       Date:  2018-02-03       Impact factor: 12.479

6.  Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches.

Authors:  Jing Huang; Yuancheng Li; Anamaria Orza; Qiong Lu; Peng Guo; Liya Wang; Lily Yang; Hui Mao
Journal:  Adv Funct Mater       Date:  2016-02-05       Impact factor: 18.808

Review 7.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

8.  Treatment of glioblastoma using multicomponent silica nanoparticles.

Authors:  O Turan; P A Bielecki; V Perera; M Lorkowski; G Covarrubias; K Tong; A Yun; Georgia Loutrianakis; S Raghunathan; Y Park; T Moon; S Cooley; D Dixit; M A Griswold; K B Ghaghada; P M Peiris; J N Rich; E Karathanasis
Journal:  Adv Ther (Weinh)       Date:  2019-09-04

9.  Radiofrequency-Triggered Drug Release from Nanoliposomes with Millimeter-Scale Resolution Using a Superimposed Static Gating Field.

Authors:  Jessica F Liu; Nishant Neel; Phillip Dang; Max Lamb; Jaime McKenna; Lauren Rodgers; Brian Litt; Zhiliang Cheng; Andrew Tsourkas; David Issadore
Journal:  Small       Date:  2018-10-04       Impact factor: 13.281

Review 10.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.